Dianthus Therapeutics (DNTH) Research & Development (2017 - 2025)

Dianthus Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $32.5 million for Q3 2025.

• On a quarterly basis, Research & Development rose 27.19% year-over-year to $32.5 million in Q3 2025; TTM through Sep 2025 was $117.0 million, a 78.62% increase from a year earlier, with the FY2024 full-year figure at $87.9 million, up 167.65% from the prior year.
• Research & Development climbed to $32.5 million in Q3 2025 per DNTH's latest filing, from $26.3 million in the prior quarter.
• Across five years, Research & Development topped out at $32.5 million in Q3 2025 and bottomed at $5.8 million in Q1 2023.
• The 5-year median for Research & Development is $11.7 million (2021), against an average of $15.7 million.
• Across the five-year window, Research & Development slumped 64.66% in 2023 and soared 255.4% in 2024, its largest moves.
• Year by year, Research & Development stood at $13.1 million in 2021, then declined by 25.03% to $9.8 million in 2022, then slipped by 10.68% to $8.8 million in 2023, then surged by 255.4% to $31.2 million in 2024, then grew by 4.1% to $32.5 million in 2025.
• Per Business Quant, the three latest DNTH Research & Development figures stand at $32.5 million (Q3 2025), $26.3 million (Q2 2025), and $27.0 million (Q1 2025).